These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 26194447)

  • 21. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
    Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Arora M; Cutler CS; Jagasia MH; Pidala J; Chai X; Martin PJ; Flowers ME; Inamoto Y; Chen GL; Wood WA; Khera N; Palmer J; Duong H; Arai S; Mayer S; Pusic I; Lee SJ
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):449-55. PubMed ID: 26541363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
    Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic graft versus host disease but not the intensity of conditioning has impact on survival after allogeneic hematopoietic stem cell transplantation for advanced hematological diseases.
    Hilgendorf I; Wolff D; Nogai A; Kundt G; Hahn J; Holler E; Uharek L; Junghanss C; Leithäuser M; Thiel E; Freund M; Kahl C
    Onkologie; 2012; 35(9):487-92. PubMed ID: 23007145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT.
    Takano K; Fuji S; Uchida N; Ogawa H; Ohashi K; Eto T; Sakamaki H; Morishima Y; Kato K; Suzuki R; Fukuda T
    Bone Marrow Transplant; 2015 Apr; 50(4):553-8. PubMed ID: 25621798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation.
    Terakura S; Murata M; Nishida T; Emi N; Akatsuka Y; Riddell SR; Morishima Y; Kodera Y; Naoe T
    Br J Haematol; 2005 Apr; 129(2):221-8. PubMed ID: 15813850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.
    Thakar MS; Broglie L; Logan B; Artz A; Bunin N; Burroughs LM; Fretham C; Jacobsohn DA; Loren AW; Kurtzberg J; Martinez CA; Mineishi S; Nelson AS; Woolfrey A; Pasquini MC; Sorror ML
    Blood; 2019 Feb; 133(7):754-762. PubMed ID: 30545834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing.
    Giebel S; Giorgiani G; Martinetti M; Zecca M; Maccario R; Salvaneschi L; Holowiecki J; Locatelli F
    Bone Marrow Transplant; 2003 Jun; 31(11):987-93. PubMed ID: 12774049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
    MacMillan ML; Robin M; Harris AC; DeFor TE; Martin PJ; Alousi A; Ho VT; Bolaños-Meade J; Ferrara JL; Jones R; Arora M; Blazar BR; Holtan SG; Jacobsohn D; Pasquini M; Socie G; Antin JH; Levine JE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):761-7. PubMed ID: 25585275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
    Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
    J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
    Aldenhoven M; Jones SA; Bonney D; Borrill RE; Coussons M; Mercer J; Bierings MB; Versluys B; van Hasselt PM; Wijburg FA; van der Ploeg AT; Wynn RF; Boelens JJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1106-9. PubMed ID: 25708213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.
    Miller HK; Braun TM; Stillwell T; Harris AC; Choi S; Connelly J; Couriel D; Goldstein S; Kitko CL; Magenau J; Pawarode A; Reddy P; Riwes M; Yanik GA; Levine JE
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):522-528. PubMed ID: 28017733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index.
    Bashey A; Zhang X; Jackson K; Brown S; Ridgeway M; Solh M; Morris LE; Holland HK; Solomon SR
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):125-33. PubMed ID: 26359881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.
    Holtan SG; Zhang L; DeFor TE; Bejanyan N; Arora M; Rashidi A; Lazaryan A; Kotiso F; Blazar BR; Wagner JE; Brunstein CG; MacMillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1884-1889. PubMed ID: 31128328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation.
    Ringdén O; Labopin M; Gorin NC; Volin L; Torelli GF; Attal M; Jouet JP; Milpied N; Socié G; Cordonnier C; Michallet M; Atienza AI; Hermine O; Mohty M;
    Br J Haematol; 2012 Apr; 157(2):220-9. PubMed ID: 22299728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
    Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
    J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.